3021 New manioc allergens and successful oral immunotherapy in a brazilian allergic patient

Tuesday, 9 December 2014: 12:20 - 12:40
Exhibition Hall-Poster Area (Sul America)

Keity Souza Santos, PhD , Laboratory of Clinical Immunology and Allergy-LIM60, Division of Clinical Immunology and Allergy, Department of Medicine, University of São Paulo School of Medicine - FMUSP, São Paulo, Brazil

Roberta Almeida Castro, MD , Division of Immunology and Allergy - Clinics Hospital of FMUSP, University of São Paulo School of Medicine - FMUSP, São Paulo, Brazil

Gabriele Gadermaier, PhD , Christian Doppler Laboratory for Allergy Diagnosis and Therapy, University of Salzburg, Salzburg, Austria

Clóvis E S Galvão, MD, PhD , Division of Immunology and Allergy - Clinics Hospital of FMUSP, University of São Paulo School of Medicine - FMUSP, São Paulo, Brazil

Adriano Mari, MD, PhD , Center for Molecular Allergology, Idi-Irccs, Rome, Italy

Fatima Ferreira, PhD , Christian Doppler Laboratory for Allergy Diagnosis and Therapy, University of Salzburg, Brazil

Jorge Kalil, PhD , Department of Allergy and Immunology, University of São Paulo, São Paulo, Brazil

Fabio Fernandes Morato Castro, PhD , Department of Allergy and Immunology, University of São Paulo, São Paulo, Brazil

Ariana Yang, PhD , Department of Allergy and Immunology, University of São Paulo, São Paulo, Brazil

Background: Exotic tropical fruits and plants are highly consumed in Brazil and due to globalization these products are being exported worldwide. We have recently described the first manioc allergen Man e 5 that cross-reacts with Hev b 5 from latex. There are more than 70 products made up manioc starch such as drugs, soaps and fabrics and manioc allergic patients present from mild to severe reactionsMethods:  Five patients with manioc allergy confirmed by skin prick test (SPT) and oral challenge were selected. These patients were evaluated through SPT and Immunocap to latex, ELISA and ISAC inhibition with manioc extract and rMan e 5.  Among these patients we selected a Brazilian woman that lives in North region where manioc is consumed in a daily diet for an oral immunotherapy (OIT) protocol. The patient is a hairdresser, 48 years old, IgE mediated latex allergy. Six years ago she started to have episodes of anaphylaxis to manioc, but more recently she began to present allergic manifestations after inhalatory exposition to manioc starch. Patient was then submitted to OIT with manioc starch solubilized in 10mg/mL. Immunotherapy was divided in two parts: induction and maintenance. In the first phase dose was weekly increased starting with 0.1mL of a 10mg/mL until reaching an amount of 10g of manioc starch. At this point the patient was submitted to oral provocation with 100g of manioc. For maintenance it was indicated daily ingestion of foods prepared with manioc. Clinical evaluation, skin tests and IgE levels after 1 and 6 months were performed. Results: All five patients had anaphylaxis to manioc with IgE sensitization to manioc and latex. Inhibition assays showed that rMan e 5 is not the only manioc allergen and that there is a molecule in manioc cross-reacting with Hev b 6. After OIT patient presented a decrease of the wheal in SPT (10 to 4mm) and also in IgE levels to latex. Oral provocation was negative. Reactions during treatment were mild (abdominal pain and oral itching) and solved spontaneously or using antihistaminic. After two years under maintenance patient keeps asymptomatic eating manioc without restrictions. Conclusions: There are at least two manioc allergens cross-reacting with latex. OIT was proved to be safe and efficient in this case allowing free ingestion of manioc leading us to conduct the protocol with other patients. Levels of latex IgE also decreased after treatment. Knowledge of single allergens is important for diagnosis and also to monitor therapeutic success.